Aequus Pharmaceuticals Inc (AQS.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 44 | 242 | 170 | 112 | 30 |
| Receivables | 120 | 36 | 32 | 70 | 11 |
| Inventories | 162 | 77 | 124 | 184 | 32 |
| Other current assets | 45 | 45 | 45 | 45 | 45 |
| TOTAL | $425 | $475 | $436 | $487 | $166 |
| Non-Current Assets | |||||
| PPE Net | 584 | 618 | 651 | 685 | 719 |
| TOTAL | $584 | $618 | $651 | $685 | $719 |
| Total Assets | $1,009 | $1,092 | $1,086 | $1,172 | $885 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 5,555 | 5,005 | 4,370 | 3,370 | 2,600 |
| Accounts payable and accrued liabilities | 348 | 339 | 274 | 496 | 239 |
| Accrued Expenses | 80 | 29 | 42 | 176 | 101 |
| TOTAL | $6,100 | $5,487 | $4,796 | $4,146 | $3,039 |
| Non-Current Liabilities | |||||
| TOTAL | $523 | $553 | $584 | $612 | $640 |
| Total Liabilities | $6,623 | $6,040 | $5,380 | $4,759 | $3,679 |
| Shareholders' Equity | |||||
| Common Shares | 23,991 | 23,991 | 23,991 | 23,991 | 23,991 |
| Retained earnings | -34,029 | -33,346 | -32,684 | -31,968 | -31,165 |
| Other shareholders' equity | 4,425 | 4,407 | 4,400 | 4,391 | 4,380 |
| TOTAL | $-5,614 | $-4,948 | $-4,294 | $-3,587 | $-2,794 |
| Total Liabilities And Equity | $1,009 | $1,092 | $1,086 | $1,172 | $885 |